Business Wire

Astra Announces Spacecraft Engine Contract with Airbus OneWeb Satellites

Share

Astra Space, Inc. (“Astra”) (Nasdaq: ASTR), a provider of space products and launch services to the global space industry, today announced that it has been selected by Airbus OneWeb Satellites, LLC (“AOS”) to supply the Astra Spacecraft Engine™ for integration into the portfolio of Arrow commercial small satellites manufactured by AOS.

Airbus OneWeb Satellites LLC is a joint venture between Airbus and OneWeb. AOS manufactures satellites for the OneWeb commercial constellation and Airbus customers in Merritt Island, Florida. AOS is producing satellites for Airbus U.S. Space & Defense, Inc., in support of U.S. government programs.

About Astra:

Astra’s mission is to Improve Life on Earth from Space® by creating a healthier and more connected planet. Today, Astra offers one of the lowest cost-per-launch dedicated orbital launch services of any operational launch provider in the world, and one of the industry’s first flight-proven electric propulsion systems for satellites, Astra Spacecraft Engine™. Astra delivered its first commercial launch to low Earth orbit in 2021, making it the fastest company in history to reach this milestone, just five years after it was founded in 2016. Astra (NASDAQ: ASTR) was the first space launch company to be publicly traded on Nasdaq. Visit astra.com to learn more about Astra.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Kati Dahm
media@astra.com

Investor Contact:
Andrew Hsiung
investors@astra.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Strong growth, but lower margins for Jotun6.10.2022 21:00:00 CEST | Press release

Jotun increased both operating revenue and operating profit year to date. However, the operating margin was challenged by high raw material prices and significant global unrest. Market status Increased sales volume and prices led to strong topline growth for Jotun during the first and second tertiary 2022. Operating revenue came in at NOK 18 243 million, up 22 per cent from the same period last year. All segments (Decorative Paints, Protective Coatings, Marine Coatings and Powder Coatings) delivered double-digit sales growth. “We are satisfied with the development. It is great to see that the marine newbuilding market has recovered after a difficult period. We also see sales improving within ship maintenance products, protective coatings and decorative paints,” President & CEO Morten Fon says. Global challenges The positive development comes in a time of major global challenges. The war in Ukraine is affecting the raw material markets and creating an energy crisis in Europe. In additio

ProDERM Study Results of octagam ® 10% Treatment in Patients With Dermatomyositis Published in the New England Journal of Medicine6.10.2022 18:33:00 CEST | Press release

Octapharma announced today the results from the ProDERM study on the efficacy and safety of octagam® 10% [Immune Globulin Intravenous (Human)], in adult dermatomyositis (DM) patients have been published in the New England Journal of Medicine (Aggarwal R et al. “Efficacy and safety of intravenous immunoglobulin in dermatomyositis”). Dermatomyositis is an immune-mediated myopathy characterised by chronic inflammation of the skin and muscles, leading to cutaneous rashes and progressive muscle weakness. DM is associated with increased morbidity and mortality due to muscle weakness and visceral involvement. Prior to the ProDERM study findings, no therapy had been approved in the US or Europe for the treatment of dermatomyositis based on randomized clinical trials. The Progress in DERMatomyositis (ProDERM) study was the first large randomized clinical trial to investigate an intravenous immunoglobulin (IVIg) (octagam® 10%) in dermatomyositis. The results of the study demonstrated that octaga

New Visa Reports Underscore Importance of Cybersecurity Amid Shifting Threats6.10.2022 17:34:00 CEST | Press release

Visa Inc. (NYSE:V), the world leader in digital payments, today shared an updated look at how fraud has evolved since the height of the pandemic, with criminals simultaneously targeting online and offline vulnerabilities as our daily lives return to a blend of in-person and e-commerce experiences. “As in-person commerce returns to pre-pandemic levels, crooks are back to exploiting the physical points of vulnerability in stores, while continuing to capitalize on e-commerce through malware, ransomware and phishing attacks, among others,” said Paul D. Fabara, Chief Risk Officer at Visa. “In fact, we are continuing to see high rates of skimming, growing over the already elevated levels of the winter of 2021, where fraudsters are jumping on the rise of in-person activity.” Two new pieces of research – the latest Visa Biannual Threats Report and an MIT Technology Review Insights study “Moving Money in a Digital World,” released today in partnership with Visa – highlight new and returning thr

Eurosets Presents Colibrì, the Lightest and Most Compact ECLS System in the Market Which May Be Transported Even in a Backpack6.10.2022 17:24:00 CEST | Press release

Eurosets, a company based in Medolla (Italy) leader in the development, production, and commercialization of advanced medical devices, announced during the 36th European Association for Cardiothoracic Surgery (EACTS) annual meeting (Milan, 5th-8th October 2022) the launch of Colibrì, the lightest extracorporeal life support (ECLS) system available in the market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221003005921/en/ Ettore Sansavini, Eurosets President, and Antonio Petralia, Eurosets CEO, next to the Colibrì (Photo: Business Wire) Colibrì complements and expands Eurosets ECLS portfolio with the objective to provide temporary support to patients suffering from ventricular failure, cardiac arrest, or respiratory failure in a variety of different applications, including extracorporeal membrane oxygenation (ECMO), extracorporeal cardiopulmonary resuscitation (E-CPR), and mechanical circulatory support (MCS). Featuring a

Five-Year GSA Contract Expands Raisbeck’s Footprint in Government Arena6.10.2022 16:21:00 CEST | Press release

Raisbeck Engineering, a leading provider of performance enhancement systems for business, commercial and military aircraft, today announced that it has been awarded a General Service Administration Multiple Award Schedule contract (MAS). The contract, which took effect September 30, 2022, is valid for five years with three five-year option periods. The GSA Schedule is significant in that it makes the company’s products accessible through a simplified buying process to state and federal government agencies, expanding the company’s footprint in the federal government marketplace. To qualify for GSA approval, the company went through a rigorous 18-month application process. Contractors selling through the GSA contract are carefully vetted beforehand and must have a proven track record within its industry. The GSA Multiple Award Schedule also provides a competitive advantage in the government sector since terms and conditions including pricing and warranties are previously agreed upon. “We

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom